A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective

When taken consistently, pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) with once daily tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) has been shown to safely reduce the incidence of HIV infection in high-risk individuals by more than 90%. Yet, according to the Ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Jennifer L., Molino, Suzanne T., Vega, Ana D., Badowski, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595773/
https://www.ncbi.nlm.nih.gov/pubmed/28600755
http://dx.doi.org/10.1007/s40121-017-0159-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595773/
https://www.ncbi.nlm.nih.gov/pubmed/28600755
http://dx.doi.org/10.1007/s40121-017-0159-9

Ejemplares similares